Business Wire

Rochon Genova LLP: Did You Purchase Shares of Aphria Inc. (“Aphria”) After January 29, 2018 and Hold Them Until March 23, 2018 and/or December 3, 2018?

10.2.2025 14:00:00 CET | Business Wire | Press release

Share

A Settlement has been reached in the global class action (the “Class Action”) against Aphria and certain of its former officers and directors (“Individual Defendants”) announces Rochon Genova LLP. The Settlement requires Court approval at an upcoming hearing.

The Class Action alleges that, between January 29, 2018 and December 3, 2018, Aphria and the Individual Defendants made public misrepresentations to the capital markets, including in an Aphria Prospectus Offering in June 2018, in connection with two significant international business acquisitions made by Aphria during 2018, namely: (i) Aphria’s acquisition of a company called Nuuvera Inc. which was publicly announced on January 29, 2018; and (ii) Aphria’s acquisition of a company called LATAM Holdings Inc. which was publicly announced on July 17, 2018. The Class Action alleges that the substantial drop in Aphria’s share price following certain public disclosures about Aphria’s business on March 22 and on December 3, 2018, amounted to a public correction of misrepresentations about Aphria’s business.

Aphria and the Individual Defendants deny all allegations pleaded against them in the Class Action.

The Settlement, if approved by the Court, provides for the payment by the Defendants of the total amount of CAD $30,000,000 to resolve the Class Action. The Settlement is a compromise of disputed claims and is not an admission of liability or wrongdoing by Aphria or the Individual Defendants.

The Settlement will be considered for approval by the Ontario Superior Court of Justice at a Settlement Approval Hearing which has been set for March 26, 2025 in Toronto at 11:30 am. At the Hearing, the Court will also address a motion to approve Class Counsel’s fees, which will not exceed 30% of the settlement amount plus reimbursement for expenses incurred in the Class Action.

Persons who purchased Aphria shares on or after January 29, 2018 and held them on March 23 and/or December 3, 2018 (“Class Members”) may object to or support the Settlement, by making a submission in writing prior to March 14, 2025. Class Members may also attend the Settlement Approval Hearing in person or remotely via Zoom. For more information about your rights and how to speak to the Settlement, please see the Long-Form Notice available online at www.AphriaSettlement.com or call toll-free: 1-888-700-9930.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250210825594/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA29.4.2026 12:00:00 CEST | Press release

TEVIMBRA plus ZIIHERA and chemotherapy regimen delivered statistically significant median OS of 26.4 months, an unprecedented result in this challenging diseaseResults from the global Phase 3 HERIZON-GEA-01 study demonstrate potential to change clinical practice in advanced HER2+ gastroesophageal adenocarcinoma BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to a supplemental Biologics License Application (sBLA) for TEVIMBRA® (tislelizumab) in combination with ZIIHERA® (zanidatamab) and chemotherapy for the first-line treatment of unresectable locally advanced/metastatic HER2-positive (HER2) gastric, gastroesophageal junction, or esophageal adenocarcinoma. The FDA has also granted Breakthrough Therapy Designation to the regimen of ZIIHERA in combination with fluoropyrimidine- and platinum-containing chemotherapy, with and without TEVIMBRA, in this indica

European Commission (EC) Approves Henlius and Organon’s POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe29.4.2026 11:30:00 CEST | Press release

Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for POHERDY® (pertuzumab) 420 mg/14 mL injection for intravenous use, the first and only approved biosimilar to PERJETA (pertuzumab) in Europe, for all indications of the reference product.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429686426/en/ “As the first, and currently the only, pertuzumab biosimilar in Europe, the EC’s approval of POHERDY marks an important milestone in expanding access to treatments for patients with certain HER2-positive breast cancers, particularly as breast cancer is the most commonly diagnosed cancer among women in the European Union,” said Joe Azzinaro, Vice President, Global Commercial Lead Biosimilars, at Organon.2,3 “Organon’s growing global portfolio of biosimilars reinforces our ongoing commitment to supporting the sustainability of healt

Andreas Goppelt Appointed Managing Director of OrphaCare29.4.2026 10:27:00 CEST | Press release

OrphaCare, a global specialist for the development and marketing of medical devices for drug delivery and part of the AOP Health Group, has appointed Andreas Goppelt as its new Managing Director, succeeding Georg Fischer. In this role, the seasoned medical device expert will focus on broadening the company’s strategic scope and driving its next phase of growth. OrphaCare plays a key role in supporting AOP Health’s integrated therapies approach, and the Group’s long-term expansion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429303533/en/ Portrait Andreas Goppelt, Managing Director OrphaCare (copyright: AOP Health/Studio Koekart) Andreas Goppelt brings more than 25 years of leadership experience across MedTech, biotechnology and the pharmaceutical industry. He has a proven track record of driving innovation, scaling global organizations, and delivering growth in highly regulated healthcare environments. In his new role,

The Jury Has Been Announced for the Third Edition of the Reply AI Film Festival, Dedicated to the Best Short Films Generated With Artificial Intelligence29.4.2026 10:00:00 CEST | Press release

Gabriele Salvatores, together with Rob Minkoff, Catherine Hardwicke, Jed Weintrob, Christina Lee Storm, Nils Hartmann, Guillem Martinez Roura, Filippo Rizzante, Giacomo Mineo, Brian Welk and Denise Negri, will judge the short films in competition based on creativity, production quality and the use of Artificial Intelligence. Reply [EXM, STAR: REY], an international group specialized in creating new business models enabled by AI and long committed to guiding younger generations in exploring emerging technologies, presents the jury of the third edition of the Reply AI Film Festival, the international competition aimed at creatives, directors, and filmmakers who want to challenge themselves in producing short films created using Artificial Intelligence tools. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429288361/en/ “Imaginatio Nova” is the theme of the 2026 edition, an invitation to explore a new phase of imagination, wh

Bregal Milestone Announces Majority Growth Investment in CoreGo, a Leading European Open-Loop Payment and Event Technology Company29.4.2026 10:00:00 CEST | Press release

Investment follows over 98% annual growth and supports CoreGo’s continued market expansion Bregal Milestone, a leading European software growth private equity firm, today announced a majority strategic growth investment in CoreGo Oy ("CoreGo" or the "Company"), a leading provider of open-loop payments and integrated technology solutions for festivals, sports events, and venues across Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427991105/en/ Founded in Helsinki in 2015 by Hannu Elomaa and CTO Nikoteemu Väänänen, CoreGo has built one of Europe's most differentiated open-loop payment infrastructure and event technology businesses. Serving approximately 250 customers across the Nordics and DACH region, the Company delivers an integrated showtime-critical suite of solutions through CoreGo Cloud, unifying payments, access, networks, and data into a single real-time operating system. CoreGo’s in-house private network

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye